Skip to content

Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate

Diclofenac Suppository As a Preemptive Analgesia in Ultrasound Guided Biopsy of Prostate: Randomized Controlled Trial

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01939743
Enrollment
100
Registered
2013-09-11
Start date
2011-10-31
Completion date
2012-10-31
Last updated
2013-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma Prostate

Brief summary

Transrectal ultrasound guided biopsy of prostate (TRUS-Bx) is widely used as accepted mode of investigation for prostate cancer in current urology practice. It is considered a minor procedure, which most of the patients tolerate, however 20% of patients refuse to undergo the redo procedure without any analgesia or anesthesia but on the other hand, some authors reveal that 65 to 90% of patients report pain ranging from mild to severe in intensity. Diclofenac is a local and systemic anti-inflammatory drug and it reduces local mediators involved in local pain.The purpose of this study is to find out the role of rectal administration of diclofenac suppositories as an adjunct to 2% xylocaine gel in alleviating intra and post procedural pain in prostatic biopsy with adequately calculated sample size and excluding the patients with contraindication to procedure or diclofenac administration as these were the shortcomings of previous studies.

Interventions

DRUGDiclofenac suppository plus lidocaine gel
DRUGLidocaine gel only

Sponsors

Aga Khan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
51 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

All male patients undergoing ultrasound guided prostate biopsy due to any one of the following: * Raised prostate-specific antigen level (\>4.0ng/ml) and palpable nodularity on digital rectal examination * Palpable nodularity on digital rectal examination * Hypo echoic lesion as compared to surrounding prostate on transrectal ultrasound

Exclusion criteria

* History of previous prostate biopsy * Acute and/or chronic prostatitis or chronic pelvic pain syndrome * Anal fissure, hemorrhoids, anal surgery * Concomitant analgesic medication * Chronic renal failure * Allergy to diclofenac

Design outcomes

Primary

MeasureTime frame
Pain on visual analog scoreTwo hours

Secondary

MeasureTime frame
Adverse effects of diclofenac suppositorytwo hours

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026